 CytomX Therapeutics Incs NASDAQ: CTMX Phase 2 study of praluzatamab ravtansine in hormone receptor-positive HRhuman epidermal growth factor receptor 2 HER2-non-amplified breast cancer Arm A met its primary efficacy endpoint of confirmed objective response rate ORR. 